Children with atopic dermatitis show increased activity of β-glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu

Sanja Kezic,1 Maeve A. McAleer,2,3 Ivone Jakasa,4 Susan M.I. Goorden,5 Karen Ghauharali-vander Vlugt,5 Femke S. Beers-Stet,5 Judith Meijer,5 Jeroen Roelofsen,5 Monique M. Nieman,5 André B.P.van Kuilenburg5 and Alan D. Irvine6

1Amsterdam UMC, University of Amsterdam, Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands
2Clinical Medicine, Trinity College Dublin, Dublin, Ireland
3Paediatric Dermatology, Children’s Health Ireland at Crumlin, Dublin, 12, Ireland
4Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia
5Amsterdam UMC, University of Amsterdam, Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam, the Netherlands

Correspondence
Alan D. Irvine
Email: irvinea@tcd.ie

Accepted for publication
30 December 2021

Funding sources
The group of A.D.I. is funded by the National Children’s Research Centre, Dublin, Ireland. M.A.McA. is supported by the National Children’s Research Centre, Dublin, Ireland.

Conflicts of interest
The authors declare they have no conflicts of interest.

Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

A.B.P.vK. and A.D.I. are joint senior authors.

DOI 10.1111/bjd.20979

Summary

Background Atopic dermatitis (AD) is characterized by immune dysregulations and an impaired skin barrier, including abnormalities in lipid organization. In the stratum corneum (SC), β-glucocerebrosidase (GBA) mediates transformation of glucosylceramide (GlcCER) into ceramide (CER) and cholesterol into glucosylcholesterol (GlcChol). Alteration in GBA activity might contribute to skin barrier defects in AD. Objectives To investigate GBA activity in the SC of children with AD before and after topical corticosteroid therapy and to compare it with healthy controls; to determine SC levels of GlcCER- and CER-containing hydroxysphingosine base (GlcCER[H] and CER[H], respectively) and GlcChol, and to relate them to disease severity, skin barrier function and the local cytokine milieu. Methods Lipid markers and cytokines of innate, T helper 1 and T helper 2 immunity were determined in SC collected from healthy children and from clinically unaffected skin of children with AD, before and after 6 weeks of therapy with topical corticosteroids. AD severity was assessed by Scoring Atopic Dermatitis and skin barrier function by transepidermal water loss (TEWL). Results Baseline GBA activity and GlcChol levels were increased in children with AD but declined after therapy. CER[H] levels and the CER[H] to GlcCER[H] ratio were increased in AD. GBA activity and GlcChol correlated with TEWL and levels of multiple cytokines, especially interleukin-1α and interleukin-18. GlcChol was strongly associated with disease severity. Conclusions We show increased GBA activity and levels of GlcChol in AD. Our data suggest an important role of inflammation in disturbed lipid processing. GBA activity or GlcChol might be useful biomarkers in the monitoring of therapeutic responses in AD.

What is already known about this topic?

- Patients with atopic dermatitis (AD) have a reduced skin barrier, mainly caused by altered lipid organization.
- The mechanisms underlying these lipid anomalies are not fully understood but likely reflect both genetic abnormalities in AD skin and the local cutaneous inflammatory environment.
Atopic dermatitis (AD) is a highly prevalent inflammatory skin disease with a broad range of abnormalities in immune response and skin barrier function, even in nonlesional skin. Skin barrier function resides largely in the uppermost layer of the skin, the stratum corneum (SC), composed of anucleated cells (corneocytes), which are filled with keratin filaments aligned and aggregated by filaggrin protein. Corneocytes are wrapped in lipid envelopes with anchoring sites for lipid lamellae, which fill the intercellular space between corneocytes. Highly ordered lipid lamellae are composed of three main classes of lipids: ceramides (CER), free fatty acids and cholesterol.

Altered composition and structure of lipid lamellae are regarded as the major cause of barrier deficiency in AD. Furthermore, SC lipids, in particular CER, are key molecules in cell signalling that contribute to regulation of vital cellular functions. Given the crucial importance of the skin barrier, it is not surprising that skin is highly specialized in the biosynthesis of CER, comprising multiple pathways mediated by numerous enzymes. Several studies have shown alterations in the expression or activity of enzymes involved in elongation of fatty acids in AD, related to reduced skin barrier function. In addition, a recent study reported that AD skin has altered expression and/or activity of epidermal β-glucocerebrosidase (in this manuscript referred to as GBA), an acid β-glucosidase that mediates formation of CER from their precursor glucosylceramide (GlcCER). In the SC, GBA is the predominant glucosidase. Next to its role in formation of CER from GlcCER, GBA can catalyse transglucosylation reactions between GlcCER and cholesterol, resulting in formation of glucosylcholesterol (GlcChol) (Figure 1). To explore whether
Patients and methods

Study population

Our cohort originates from a larger study in which 100 infants with their first presentation of AD were recruited in a dedicated AD clinic in Children’s Health Ireland at Crumlin, Dublin. From the original cohort, three subgroups were randomly selected as follows: 22 children with AD and 17 healthy controls for analysis of GBA activity, 19 children with AD and nine healthy controls for GlcChol, and 17 children with AD and eight healthy controls for analysis of CER. The patients met the Hanifin and Rajka criteria for the diagnosis of AD. Severity of disease was assessed by Scoring Atopic Dermatitis (SCORAD). Objective SCORAD (oSCORAD) is derived from the SCORAD by excluding parental assessment of sleep loss and itch.

TEWL measurements were performed on an area of clinically unaffected skin on the volar forearm using the Tewameter 300 (Courage+Khazaka electronic GmbH, Cologne, Germany). The patients were treatment naive, apart from the use of emollients or over-the-counter hydrocortisone 1% cream or ointment. For controls, children were recruited when attending for elective procedures. They did not have AD, any history suggestive of AD or any other inflammatory skin disease. All patients were asked to refrain from application of any topical agents for 24 h prior to assessment.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the research ethics committee of Children’s Health Ireland at Crumlin, Dublin. Written informed consent was obtained from all patients’ parents. The demographic and clinical details of the three subgroups are presented in Table 1.

Sampling of the stratum corneum

The SC was collected using circular adhesive tapes (22-mm diameter D-Squame Discs; Monaderm, Monaco, France). The tapes were placed on nonlesional forearm skin (2 cm from the nearest lesional) of patients and healthy controls. Adhesive tapes were pressed for 10 s with a pressure of 225 g cm⁻², using a D-Squame Pressure Instrument D500 (CuDerm Corporation, Dallas, TX, USA). Sequentially, eight consecutive tape strips were collected from the same skin site, placed individually in 2-mL cryovials and immediately stored at −80 °C. For the analysis of GlcChol and GBA activity, the second consecutive tape from the same skin site was used, for CER the third tape, for NMF the fourth tape and for cytokines the fifth tape. In a subgroup of six healthy controls and six patients, GBA activity was determined in the second, sixth and eighth tapes collected at baseline.

Determination of natural moisturizing factor

The analysis of natural moisturizing factor (NMF) was performed by a previously described high-performance liquid chromatography method. NMF was normalized by protein amount, determined by the Pierce Micro BCA Protein Assay Kit (Thermo Fischer Scientific, Rockford, IL, USA).

Determination of cytokines in the stratum corneum

The method for cytokine determination is described in detail elsewhere. Briefly, cytokines were extracted from the tape with phosphate-buffered saline (Merck KGaA, Darmstadt, Germany) containing 0-005% Tween20 (Sigma Aldrich, St Louis, MO, USA). Cytokine concentrations in the extracts were measured on multiplex panels using Meso QuickPlex SQ 120 (MSD, Rockville, MA, USA). We included only cytokines with levels above the limit of detection of the method, including vascular endothelial growth factor, CCL2, CCL4, CCL13, CCL17, CCL22, CXCL8, interleukin (IL)-1a, IL-1b, II-2, IL-5, IL-13, IL-16 and IL-18. The amount of cytokine in the SC was normalized by protein amount, determined in the extracts using the Pierce Micro BCA Protein Assay Kit.

Determination of β-glucocerebrosidase activity

GBA was extracted from the tape by adding 1:2 mL 1% Triton X100 and ultrasonification (Branson 5800; Branson Ultrasonics BV, Ede, the Netherlands) for 15 min in ice water. All chemicals were obtained from Merck KGaA, except glycine (Serva, Heidelberg, Germany). GBA activity in extracts was determined in a reaction mixture (100 μL) containing 5 mmol L⁻¹ 4-methylumbelliferone-β-D-glucopyranoside, 1:5% w/v taurocholate and 0:1 mol L⁻¹ citrate/0:2 mol L⁻¹ phosphate (pH 5:5). The reaction was started by addition of 50 μL skin tape homogenate and incubated at 37 °C for 2 h. The reaction was stopped by adding 2850 μL of 0:2 mol L⁻¹ carbonate/glycine (pH 10:5). The reaction product (4-methylumbelliferone) was measured fluorometrically using a Perkin Elmer fluorescence detector (excitation 360 nm, emission 450 nm; PerkinElmer, Waltham, MA, USA). The GBA activity was normalized by protein amount, determined from optical density measured by SquameScan (CuDerm Corporation). In a pilot experiment, we proved complete inhibition of enzyme activity using CBE (conduritol B epoxide), a known GBA inhibitor.

Determination of ceramides and glucosylocholesterol

CER and sphingoid bases were extracted from the tapes by methanol–chloroform–water, 12 : 6 : 1, v/v/v. The extract was dried (N₂, 40 °C) and phase separation was induced by the addition of methanol–chloroform–100 mmol L⁻¹ ammonium formate in 20% formic acid, 1 : 1 : 1, v/v/v in order to separate the free sphingoid bases from the CER and GlcCER. The lower phase, containing CER, was dried (N₂, 40 °C) and the residue was dissolved in 500 μL of 0:1 mol L⁻¹ sodium hydroxide in methanol–chloroform–water for downstream analysis. The analysis of ceramides and glucosylocholesterol was done using a previously described high-performance liquid chromatography method. The analysis was performed by a previously described high-performance liquid chromatography method.
methanol. Next, samples were decylated by microwave-assisted deacylation exactly as described previously. After hydrolysis, samples were neutralized by addition of 50 mmol L⁻¹ hydrochloric acid in methanol, and internal standards were added to each sample [d7-sphingosine(d18:1) and d5-glucosylsphingosine(d18:1)], followed by evaporation of methanol (N2, 40 °C). Thereafter, samples were subjected to extraction with butanol–water (1 : 1, v/v). After drying the butanol phase, samples were dissolved in 120 μL methanol and analysed by liquid chromatography–tandem mass spectroscopy (LC-MS/MS).

GlcChol was extracted from the tapes by methanol–chloroform–water, 12 : 6 : 1, v/v/v and the extract was dried (N2, 40 °C). After addition of an internal standard (stigmastanol) separation of phases was induced by methanol–chloroform–water, 1 : 1 : 0.9, v/v/v according to the Bligh and Dyer method. The lower phase was transferred to a 2-mL tube and the upper phase was washed with chloroform. The combined lower phases were dried (N2, 40 °C) and the sample residues were dissolved in 150 μL of 10 mmol L⁻¹ ammonium formate in methanol prior to analysis by LC-MS/MS, the method for which has been described previously and is detailed in Table S1 (see Supporting Information).

A schematic overview of the methods used to analyse GlcChol, CER and GlcCER is provided in Figure S1 (see Supporting Information).

### Statistical analysis

Calculations were performed using Prism 8 software (GraphPad, La Jolla, CA, USA). Distribution of data was tested by the Shapiro–Wilk normality test. P values were corrected for multiple testing using a Benjamini–Hochberg procedure. The applied statistical test is indicated within the figures or legends.

### Results

Patients with AD had moderate-to-severe disease, which significantly improved after topical corticosteroid therapy (Table 1). At baseline, patients with AD had reduced skin barrier function, as assessed by TEWL, and lower NMF levels than healthy controls (Table 1). After therapy, TEWL in children with AD was still higher than in healthy controls, while NMF levels were lower. At baseline, GBA activity was significantly higher in patients with AD than in healthy controls, but it decreased after 6 weeks of therapy (Figure 2). The same pattern was observed for GlcChol; baseline values were higher in patients with AD.
than in healthy controls and decreased after therapy. We calculated the relative ratio of GlcChol before and after therapy, and the median value amounted to 0.5 (range 0.04–4.8), an average decrease of 50%. After therapy, GlcChol and GBA activity were still higher in patients with AD than in healthy controls.

To investigate a possible relationship between SC depth and activity we determined the GBA activity at three different depths (tape numbers 2, 6 and 8, collected from the same skin site) in six patients with AD at baseline and six healthy controls. As shown in Figure 3, there was a gradual increase in activity of GBA with SC depth, and this pattern was observed in both patients with AD and healthy controls. Consistently, patients with AD showed higher GBA activity than healthy controls at all investigated depths. Levels of a subclass of CER – CER[H] – the corresponding glucosylceramide GlcCER[H] and their ratio are presented in Figure 4. CER[H] levels were higher in patients with AD than in controls, while no difference between these two groups was observed for GlcCER[H]. The CER[H]-to-GlcCER[H] ratio was higher in patients with AD than in controls (Figure 4). As described in the methods section, the values of CER[H] are approximate, as for the calibration the standard of sphingosine was used due to the lack of a hydroxylated standard.

Next, we investigated whether lipid parameters were associated with disease severity, skin barrier parameters and immune response. For this purpose, we performed a Spearman’s rank correlation analysis for GBA activity and GlcChol with clinical parameters (SCORAD and oSCORAD), markers of the skin barrier (TEWL and NMF) and immunological markers (cytokines). The results of the Spearman correlation analysis including correlation coefficients and corresponding significance levels are presented as a heat map in Figure 5. The results revealed a strong association of GlcChol with oSCORAD, TEWL and NMF and most immunological markers that we had previously shown to be elevated in this cohort of children with AD. CER[H] was associated with several cytokines, including IL-18, CCL2, IL-5 and CCL4, and furthermore with NMF and TEWL (Figure 5). GlcChol was positively correlated with vascular endothelial growth factor, CCL2, CCL22, CCL17, IL-18 and CXCL8, while an inverse association was seen for IL-1α, CCL13, CCL4, IL-5, IL-2 and NMF. In contrast to GlcChol, GBA activity was not significantly correlated with disease severity, but showed a strong association with the skin barrier parameters TEWL and NMF and several immunological markers. GBA activity was positively associated with CCL2, CCL22, CCL17, IL-18 and CXCL8, while significant negative correlation was observed with NMF, CCL13 and IL-1α. In general, GBA and GlcChol showed the strongest associations with the cytokines of innate immunity: IL-1α and IL-18 (Figure 6).

Discussion

Impaired skin barrier is an important aetiological factor in AD; this study contributes to our knowledge about the interplay between the skin barrier and the local immune milieu in this highly prevalent inflammatory skin disease. We measured the activity of GBA and its enzymatic product GlcChol in the SC of children with AD before and after topical corticosteroid therapy, and related these levels to the local cytokine milieu, disease severity and skin barrier function. The results convincingly demonstrate that nonlesional skin of children with AD shows increased GBA activity and higher levels of the GBA enzymatic product, GlcChol. After 6 weeks of therapy, activity

Figure 2 Activity of β-glucocerebrosidase (GBA) and stratum corneum levels of glucosylcholesterol (GlcChol) in patients with atopic dermatitis at baseline (ADt0) and after therapy (ADt6), and in healthy controls (Ctrl) (mean and SD). Differences between values before and after therapy were tested by Wilcoxon matched-pairs signed-rank test and between patients with AD and healthy controls by two-tailed Mann–Whitney test. Benjamini–Hochberg corrected P values: *P < 0.05, **P < 0.01, ****P < 0.0001.
of GBA and GlcChol decreased significantly from baseline; however, their levels were still increased compared with whose of healthy control children. In line with increased activity of GBA and GlcChol levels, levels of a specific ceramide subclass, CER[H], and the CER[H]-to-GlcCER[H] ratio were higher in AD. Formation of CER[H], a ceramide class with 6-hydroxysphingosine as a sphingoid base, is exclusively catalysed by GBA, while conversion into the sphingosine-related subclass CER[S] is also mediated by acid sphingomyelinase. Previously, it has been shown in a human skin equivalent model that inhibition of GBA activity leads to a dose-dependent increase in the ratio of GlcCER[EOH] to CER[EOH], supporting our findings.26

GBA plays an important role in biosynthesis of CER and is essential for formation and functioning of the skin barrier. A decrease in GBA activity is associated with reduced skin barrier function,13 while inherited deficiency of GBA with complete lack of expression or enzyme activity leads to severe and life-threatening skin abnormalities as demonstrated by Gaucher disease.14 Along with precursors of CER – sphingomyelins and GlcCER – and various other biotransformation enzymes, GBA is stored in lamellar bodies and secreted into the extracellular space at the interphase of the stratum granulosum and SC shortly before keratinocytes transform into corneocytes.27 GBA activity is present throughout the outer parts of the epidermis, with predominant localization of active GBA in the extracellular space of the SC lipid matrix.26

One prior study quantitatively measured GBA activity in the SC of Japanese adult patients with AD.17 In contrast to the present study, there was no difference in GBA activity between healthy and AD skin; however, that study did not report details on disease severity, skin barrier function or sampling distance from lesional skin.17 In another study, Boer et al. reported differences in the localization, expression and activity of GBA in the epidermis between healthy and AD skin.10 Altered localization of active GBA in AD skin was mainly detected in lesional skin, while the difference between healthy and nonlesional atopic skin was inconsistent. In that study, in situ expression of active GBA was visualized across the epidermal layers; however,
in contrast to the present study only semiquantitative measures of GBA activity were ascertained. In accordance with the study of Boer et al., GBA activity also varied with SC depth in this work. We found a gradual increase of GBA activity with SC depth in nonlesional AD skin, as well as in healthy skin, and AD skin consistently showed significantly higher GBA activity than healthy skin at all investigated depths.

As GBA activity and the levels of GlcChol decreased after therapy we investigated their association with disease severity (SCORAD or oSCORAD), skin barrier function (TEWL) and levels of NMF and immunological mediators. Interestingly, activity of GlcChol, but not GBA, showed a significant correlation with disease severity (oSCORAD). Both GBA and GlcChol were positively associated with TEWL and inversely correlated with SC levels of NMF, a mixture of hygroscopic substances known to contribute to hydration and acidification of the SC.

The strong correlation of GBA and GlcChol with expression of the IL-1 family cytokines IL-1α and IL-18 is striking. IL-1α is abundant in the SC and is constitutively expressed by keratinocytes. IL-1α is often used as a measure of skin barrier damage, and in the SC, IL-1α levels decrease after challenges such as skin barrier damage with skin irritants. In our previous study in the same cohort of children, we showed, as would be expected, a significantly impaired skin barrier (e.g. increased TEWL) and lower IL-1α values in children with AD compared with healthy controls. It might be speculated that IL-1α acts as an alarmin, triggering repair mechanisms. Thus, increased production of CER through elevated activity of GBA might represent one repair mechanism aimed to restore skin barrier homeostasis. This view is further supported by the finding that skin barrier disruption significantly increased epidermal GBA mRNA levels, with a 2.8-fold increase over untreated control levels.

Another reason for altered GBA activity might be increased pH in AD skin. One of the regulators of skin pH is urocanic acid, a degradation product of the abundant epidermal protein filaggrin and a constituent of NMF. Indeed, we found reduced NMF in AD skin, and NMF levels were inversely associated with GBA activity. The optimal pH for GBA activity is 4.5, and some but not all studies have shown increased pH in AD skin. As discussed by Boer et al., GBA activity might also be affected by the presence of cofactors such as saposin C, which facilitates GlcCER degradation by GBA. Next to the markers of innate immune activation, GBA activity and GlcChol were positively associated with SC levels of the cytokines of T helper 2 immunity CCL17 and CCL22. However, the degree of correlation was not as strong as that found with IL-1α and IL-18. Another cytokine that showed association with GlcChol was IL-5, a cytokine that is mainly

| Angiogenesis marker | VEGF-A | GBA | GlcChol | CER[H] |
|---------------------|--------|-----|--------|--------|
| IL-1α               | -0.80 *** | -0.71 ** | -0.28 |
| IL-18               | 0.80 *** | 0.90 **** | 0.49 ** |
| IL-1β               | -0.11  | 0.05 | 0.01   |
| CXCL8               | 0.53 *  | 0.76 ** | 0.41   |
| CCL2                | 0.48 *  | 0.58 * | 0.16   |
| CCL22               | 0.48 *  | 0.70 ** | 0.43 *  |
| CCL17               | 0.48 *  | 0.60 * | 0.27   |
| IL-5                | -0.43  | -0.70 ** | -0.39 * |
| IL-13               | 0.06   | -0.04 | -0.13  |
| Others              |        |      |        |
| CCL13               | -0.47 * | -0.64 * | -0.25  |
| CCL4                | -0.38  | -0.66 ** | -0.59 **|
| IL-16               | 0.27   | 0.31 | -0.06  |
| IL-2                | -0.29  | -0.61 * | -0.12  |
| SCORAD              | -0.14  | 0.21 | 0.27   |
| oSCORAD             | -0.01  | 0.70 * | 0.44   |
| Biophysical markers |        |      |        |
| NMF                 | -0.62 ** | -0.60 ** | -0.62 ***|
| TEWL                | 0.62 *** | 0.72 *** | 0.46 ** |

Figure 5 Spearman correlation coefficients for the relationships between lipid markers and disease severity [Scoring Atopic Dermatitis (SCORAD) and objective SCORAD (oSCORAD)], transepidermal water loss (TEWL), stratum corneum natural moisturizing factor (NMF) and cytokine levels. Benjamini–Hochberg corrected P values: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CER[H], hydroxylated ceramides; GBA, β-glucocerebrosidase; GlcChol, glucosylcholesterol; IL, interleukin; Th2, T helper cell 2; VEGF, vascular endothelial growth factor.
produced by T helper 2 and mast cells. In our previous study we found lower IL-5 levels in the SC of children with AD than in healthy controls. Consistently with this, in the present study inverse correlation of GlcChol with IL-5 was found. Here we show that GlcChol is increased in AD and that its levels parallel GBA activity in the SC. Previously, it was shown in vitro that GBA is able to form GlcChol by transglucosylation of cholesterol, by a process that is reversible and depends on the local concentrations of cholesterol, CER and GlcCER. The role of GlcChol in skin barrier function and the pathophysiology of AD is unknown, but increased water solubility due to glucosylation of cholesterol might affect the organization of lipid lamellae. Similarly to GlcChol, another water-soluble cholesterol derivative, cholesterol sulfate, is increased in AD. Cholesterol sulfate is important in regulation of differentiation and desquamation; however, its generation is mediated by another enzyme, cholesterolsulfotransferase. Future research will be needed to reveal whether elevated levels of GlcChol contribute to skin barrier defects in AD, like cholesterol sulfate does.

To conclude, this study shows that SC in nonlesional skin of patients with AD has increased activity of GBA, an important enzyme for biosynthesis of CER in the SC. Consistently, increased activity of GBA is paralleled by elevated levels of its enzymatic product GlcChol. Local anti-inflammatory therapy corrects this increased GBA activity and SC levels of GlcChol, and both markers show strong association with the local immune milieu, and GlcChol also with disease severity. These findings, taken together, suggest that increased GBA activity in AD is both acquired and modifiable. Therefore, GBA activity and GlcChol might be useful biomarkers in monitoring of therapeutic responses in AD. Further work should explore these markers before and after other AD therapies including topical calcineurin inhibitors and systemic therapies, including broad immune suppressants and targeted biologic therapies. This would help to distinguish potential pathomechanisms underlying biochemical changes in AD.

The strength of our study is that we analysed not only GBA activity, but also its substrate (GlcCER) and the enzymatic products GlcChol and CER. Moreover, to the best of our knowledge we are the first to directly compare these lipid components before and after local therapy and to relate their levels to disease severity, skin barrier function and local cytokine profile. The limitation of our study is the lack of insight into the mechanisms underlying the increase of GBA activity (e.g. due to increased expression of GBA) and the effect of other lipid enzymes and cofactors. Furthermore, we did not investigate the ratio of CER[H] to GlcCER[H] before and after therapy. The activity of GBA and the levels of CER, GlcCER and GlcChol were

**Figure 6** (a, c) Linear regression analysis between baseline values of interleukin (IL)-1α and IL-18 and activity of β-glucocerebrosidase (GBA) and glucosylcholesterol (GlcChol). (b, d) IL-1α and IL-18 values (mean and SD) before and after therapy in the respective GBA and GlcChol subgroups. ADT0, baseline in patients with AD; ADT6, values 6 weeks after therapy; CI, confidence interval; Ctrl, healthy controls. R² = regression coefficient. Differences between values before and after therapy were tested by two-tailed paired t-test, and between patients with AD and healthy controls by two-tailed t-test. Benjamini–Hochberg corrected P values: *P < 0.05, **P < 0.01, ***P < 0.001.
determined in different subgroups of the cohort, and therefore the association between these markers could not be investigated. This is the first time that GlcChol was measured in atopic skin, but its function still must be clarified.

Acknowledgments

Open access funding provided by IReL. [Correction added on 30 May 2022, after first online publication: IReL funding statement has been added.]

References

1 Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396:345–60.
2 Elias PM. Skin barrier function. Curr Allergy Asthma Rep 2008; 8:299–305.
3 Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta 2014; 1841:280–94.
4 Petrus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002; 1585:114–25.
5 Uchida Y. Ceramide signaling in mammalian epidermis. Biochim Biophys Acta 2014; 1841:453–62.
6 Rabionet M, Gorgas K, Sandhoff R. Ceramide synthesis in the epidermis. Biochim Biophys Acta 2014; 1841:422–34.
7 Danno M, Boiten W, van Drongelen V et al. Altered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum ceramide composition. J Dermatol Sci 2017; 88:57–66.
8 Berdyshyev E, Goleva E, Bronova I et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight 2018; 3:e98006.
9 Boer DEC, van Smeden J, Bouwstra JA, Aerts J. Glucocerebrosidase: functions in and beyond the lysosome. J Clin Med 2020; 9:736.
10 Boer DEC, van Smeden J, Al-Khakany H et al. Skin of atopic dermatitis patients shows disturbed β-glucocerebrosidase and acid sphingomyelinase activity that relates to changes in stratum corneum lipid composition. Biochim Biophys Acta Mol Cell Biol Lipids 2020; 1865:158673.
11 Boer DEC, Mirzaian M, Ferraz MJ et al. Glucosylated cholesterol in skin: synthetic role of extracellular glucocerebrosidase. Clin Chim Acta 2020; 510:707–10.
12 Akiyama H, Kobayashi S, Hirabayashi Y, Murakami-Murofushi K. Cholesterol glucosylation is catalyzed by transglucosylation reaction of β-glucosidase 1. Biochim Biophys Acta 2013; 1841:838–43.
13 Imokawa G, Abe A, Jin K et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Investig Dermatol 1991; 96:523–6.
14 Elias PM, Williams ML, Croninie D, Schmuth M. Inherited clinical disorders of lipid metabolism. Curr Probl Dermatol 2010; 39:30–88.
15 Stone DL, Carey WF, Christodoulou J et al. Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed 2000; 82:F163–6.
16 Holleran WM, Takagi Y, Menon GK et al. Permeability requirements regulate epidermal beta-glucocerebrosidase. J Lipid Res 1994; 35:905–12.
17 Imokawa G. Cutting edge of the pathogenesis of atopic dermatitis: sphingomyelin deacylase, the enzyme involved in its ceramide deficiency, plays a pivotal role. Int J Mol Sci 2021; 22:1613.
18 McAleer MA, Jakasa I, Hurault G et al. Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis. Br J Dermatol 2019; 180:586–96.
19 Dapic I, Jakasa I, Yau NLH et al. Evaluation of an HPLC method for the determination of natural moisturizing factors in the human stratum corneum. And Lett 2013; 46:2133–44.
20 Legler G. Glycoside hydrolases: mechanistic information from studies with reversible and irreversible inhibitors. Adv Carbohydr Chem Biochem 1990; 48:319–84.
21 Mirzaian M, Wisse P, Ferraz MJ et al. Simultaneous quantitation of sphingoid bases by UPLC-ESI-MS/MS with identical 13C-encoded internal standards. Clin Chim Acta 2017; 466:178–84.
22 Groener JE, Pootrees B, Kuiper S et al. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chim Acta 2007; 37:742–7.
23 Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochim Physiol 1959; 37:911–17.
24 Gold H, Mirzaian M, Dekker N et al. Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultraperformance liquid chromatography–tandem mass spectrometry. Clin Chim Acta 2013; 59:547–56.
25 Marques AR, Mirzaian M, Akiyama H et al. Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular β-glucosidases. J Lipid Res 2016; 57:451–63.
26 van Smeden J, Dijkhoff IM, Helder RWJ et al. In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling. J Lipid Res 2017; 58:1239–309.
27 Breiden B, Sandhoff K. The role of sphingolipid metabolism in cutaneous permeability barrier formation. Biochim Biophys Acta 2014; 1841:441–52.
28 Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014; 134:793–9.
29 Wood LC, Elias PM, Calhoun C et al. Barrier disruption stimulates interleukin-1α expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol 1996; 106:397–403.
30 Angelova-Fischer I, Becker V, Fischer TW et al. Tandem repeated irritation in aged skin induces distinct barrier perturbation and cytokine profile in vivo. Br J Dermatol 2012; 167:787–93.
31 Koppe SA, Ljubojevic Hadzavigdovic S, Jakasa I et al. Stratum corneum profiles of inflammatory mediators in patch test reactions to common contact allergens and sodium laurel sulfate. Br J Dermatol 2017; 176:1533–40.
32 McAleer MA, Jakasa I, Stefanovic N et al. Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis. Br J Dermatol 2021; 185:153–63.
33 Darby SG, Cork MJ. pH in atopic dermatitis. Curr Probl Dermatol 2018; 54:95–107.
34 Yanagibashi T, Satoh M, Nagai Y et al. Allergic diseases: from bench to clinic – contribution of the discovery of interleukin-5. Cytokine 2017; 98:59–70.
35 Emmert H, Baurecht H, Thielking F et al. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. Exp Dermatol 2021; 30:1398–408.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Figure S1 Schematic overview of glucosylcholesterol and sphingolipid analysis.

Table S1 Liquid chromatography–tandem mass spectrometry settings for sphingolipids and glucosylcholesterol.